438 related articles for article (PubMed ID: 18288997)
1. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
2. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
3. [Indications and current development of new targeted therapies in pediatric oncology].
Leblond P; Geoerger B
Bull Cancer; 2011 May; 98(5):527-39. PubMed ID: 21596652
[TBL] [Abstract][Full Text] [Related]
4. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
5. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
7. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
[No Abstract] [Full Text] [Related]
8. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in the treatment of advanced/metastatic NSCLC.
Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
[TBL] [Abstract][Full Text] [Related]
10. Rationale and clinical results of multi-target treatments in oncology.
Sartore-Bianchi A; Ricotta R; Cerea G; Maugeri MR; Siena S
Int J Biol Markers; 2007; 22(1 Suppl 4):S77-87. PubMed ID: 17520585
[TBL] [Abstract][Full Text] [Related]
11. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
13. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A; Bui B
Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
[TBL] [Abstract][Full Text] [Related]
14. Protein kinases as drug targets in cancer.
Arslan MA; Kutuk O; Basaga H
Curr Cancer Drug Targets; 2006 Nov; 6(7):623-34. PubMed ID: 17100568
[TBL] [Abstract][Full Text] [Related]
15. In pursuit of new anti-angiogenic therapies for cancer treatment.
Cai J; Han S; Qing R; Liao D; Law B; Boulton ME
Front Biosci (Landmark Ed); 2011 Jan; 16(3):803-14. PubMed ID: 21196204
[TBL] [Abstract][Full Text] [Related]
16. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
17. [Lung cancer].
Fischer B; Buhl R
Med Klin (Munich); 2008 May; 103(5):311-20. PubMed ID: 18484217
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapy for metastatic renal cell carcinoma.
Patel PH; Chaganti RS; Motzer RJ
Br J Cancer; 2006 Mar; 94(5):614-9. PubMed ID: 16465192
[TBL] [Abstract][Full Text] [Related]
19. Early clinical studies of novel therapies for thyroid cancers.
Sherman SI
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):511-24, xi. PubMed ID: 18502340
[TBL] [Abstract][Full Text] [Related]
20. [KIT and KIT: from biology to clinical use].
Curtit E; Mansi L; Viel E; Dobi E; Chaigneau L; Nguyen T; Pivot X; Blay JY; Kalbacher E
Bull Cancer; 2012 Feb; 99(2):191-7. PubMed ID: 21669561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]